MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that it has entered into a binding Letter of Intent with HL Pharma Pty Ltd. for the importation and distribution of the Company's medicinal cannabis products in Australia.
MMJ PhytoTech Ltd
MMJ PhytoTech Limited (ASX:MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through three business units, strategically located in favourable jurisdictions with supportive regulatory frameworks in place.
United Greeneries Holding Ltd. has established world-class growing facilities in Canada, including the fully licensed Duncan Facility. MMJ is the first Australian-based company to receive a Canadian medicinal cannabis cultivation licence, and one of only a few companies globally with the capacity to commercially cultivate medicinal grade cannabis in a federally regulated environment.
The Company’s European, cannabis-based, pharmaceutical, nutraceutical and cosmetics division operates under its 100% owned subsidiary, Satipharm AG. MMJ began production of its Gelpell (R) Microgel Capsules in May 2015, and is committed to boosting the sales of its flagship product throughout regulated markets globally.
MMJ’s Israel-based subsidiary, PhytoTech Therapeutics Ltd, is responsible for the Company’s R&D activities, with a key focus on the development and commercialisation of new and existing delivery systems and devices that have the potential to deliver safe, effective and measured doses of medicinal cannabis to patients.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited ("PTL"), has commenced following Health Authorities' approval, the Phase 2 clinical study into the safety and efficacy of its PTL101 capsules in treating refractory epilepsy in children.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide its quarterly activities report for the period ended 31 December 2016.
MMJ PhytoTech (ASX:MMJ) is pleased to advise that Canadian-based Harvest One Capital Corp. (CVE:WON.H) has increased its private placement to C$22 million, plus an over-allotment option of up to an additional C$3 million. Under the increased offering, Harvest One may issue up to 33,333,333 subscription receipts at a price of $0.75 per Subscription Receipt.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that Canadian-based Harvest One Capital Corp. (CVE:WON.H) has launched a C$15 million private placement to finalise the acquisition of the Company's cannabis subsidiaries United Greeneries Holdings Ltd and Satipharm AG respectively.
MMJ PhytoTech Limited (ASX:MMJ) advises in accordance with Listing Rule 3.10A, that the following securities will be released from escrow on Monday, 23 January 2017.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that its Canadian-based subsidiary, United Greeneries Ltd ("UG") has commenced cannabis growing operations at its state-of-the-art Duncan Facility.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide shareholders with this Q&A update from Managing Director Andreas Gedeon.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide the below statement following the Canadian Federal Government's Final Report into Cannabis Legalization and Regulation. The Report has been based on the findings and recommendations submitted by the Health Canada instigated Task Force.
MMJ PhytoTech Ltd (ASX:MMJ) today confirms that it has signed a definitive agreement with Canadian-based Harvest One Capital Corp. (CVE:WON). The definitive agreement outlines the sale of 100% of issued and outstanding shares of United Greeneries Holdings Ltd and Satipharm AG to Harvest One.